| Literature DB >> 25860232 |
Ladan Zand1, Samih H Nasr2, Morie A Gertz3, Angela Dispenzieri3, Martha Q Lacy3, Francis K Buadi3, Shaji Kumar3, Robert A Kyle3, Fernando C Fervenza1, Sanjeev Sethi2, David Dingli2, S Vincent Rajkumar2, Prashant Kapoor3, Arleigh McCurdy3, Nelson Leung1,3.
Abstract
In some patients with light chain deposition disease (LCDD) there is also evidence of myeloma cast nephropathy (MCN) on renal biopsy. The purpose of this study was to evaluate the renal and survival outcome of patients with concomitant diagnosis of MCN and LCDD to LCDD and MCN alone. Eighty seven patients were identified and divided into LCDD (n=45), MCN (n=29), and LCDD+ MCN (n=13). Patients with LCDD+ MCN had a worse overall survival (OS) compared to patients with LCDD (p=0.03), but similar to patients with MCN (p=0.4). Death-censored renal survival was no different amongst the groups. Presenting with acute renal failure at time of renal biopsy (HR 7.2, p=0.0002) was an independent poor renal prognostic factor while older age (HR 1.06, p=0.0002), presence of osteolytic lesions (HR 4.4, p<0.0001), and requirement for dialysis or creatinine≥5 mg/dL (HR 3.2, p=0.0006) at time of renal biopsy were independent poor prognostic factors for OS.Entities:
Keywords: Light chain deposition disease; multiple myeloma; myeloma cast nephropathy; renal disease
Mesh：
Substances：
Year: 2015 PMID： 25860232 DOI： 10.3109/10428194.2015.1040011
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022